Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase.

about

Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase.

Item

http://www.wikidata.org/entity/Q39388927

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Mutations in the PCNA-binding ...... airing the entry into S phase.

@en

Mutations in the PCNA-binding ...... airing the entry into S phase.

@nl

type

Item

label

Mutations in the PCNA-binding ...... airing the entry into S phase.

@en

Mutations in the PCNA-binding ...... airing the entry into S phase.

@nl

prefLabel

Mutations in the PCNA-binding ...... airing the entry into S phase.

@en

Mutations in the PCNA-binding ...... airing the entry into S phase.

@nl

P1476

Mutations in the PCNA-binding ...... airing the entry into S phase.

@en

P2093

Eric Vilain

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome

Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15

Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen

CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation

p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene

Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7.

A novel variant in CDKN1C is associated with intrauterine growth restriction, short stature, and early-adulthood-onset diabetes

Increased protein stability of CDKN1C causes a gain-of-function phenotype in patients with IMAGe syndrome

CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6

CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.

P2888

s13008-015-0008-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13008-015-0008-8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kleiton Silva Borges

Valerie Arboleda

P577

2015-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274695570

http://www.w3.org/2001/XMLSchema#string

P6179

1011144237

http://www.w3.org/2001/XMLSchema#string

P698

25861374

http://www.w3.org/2001/XMLSchema#string

P932

4389716

http://www.w3.org/2001/XMLSchema#string